Celea Therapeutics engages regulators ahead of Phase III deupirfenidone IPF trial
Lung function stabilised in patients who transitioned from placebo during the OLE phase of the trial.
29 September 2025
29 September 2025
Lung function stabilised in patients who transitioned from placebo during the OLE phase of the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.